Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-C: Pulsed Erlotinib with Chemotherapy in NSCLC
NCT00287989Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2004
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Response Rate. Started Nov 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00287989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287989.